CNX Resources Corporation (NYSE:CNX) Q4 2014 Earnings Conference Call - Final Transcript
Jan 30, 2015 • 10:00 am ET
Ladies and gentlemen, thank you for standing by and welcome to the Eli Lilly's and Company Q4 Earnings Call. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Chairman, President and CEO, John Lechleiter. Please go ahead, sir.
Thank you, good morning, everyone. Thank you all for joining us to discuss Eli Lilly and Company's fourth quarter 2014 earnings. I'm John Lechleiter, Lilly's Chairman, President and CEO. Joining me on today's call are Derica Rice, our Chief Financial Officer; Dr. Jan Lundberg, our President of Lilly Research Laboratories; Dr. Sue Mahony, President of Lilly Oncology; Enrique Conterno, President of Lilly Diabetes; Dave Ricks, President of Lilly Bio-Medicines; Chito Zulueta, President of Emerging Markets; Jeff Simmons, President of Elanco Animal Health; and Ilissa Rassner, Brad Robling and Phil Johnson of the Investor Relations team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. (Forward Looking Cautionary Statements) As usual, I'll begin by highlighting key events that have occurred since last quarter's call. Following FDA approval in September, we launched Trulicity in the U.S. during the fourth quarter.
We also received regulatory approval for Trulicity in Europe. We're in the process of launching in the U.K. and Germany and anticipate launches in additional EU countries over the course of this year and next. In diabetes, we also resubmitted Humalog U-200 KwikPen in the U.S. and along with Boehringer Ingelheim we received approval in Japan for both Jardiance and our insulin glargine product. In oncology, Cyramza was approved by the European commission for the treatment of advanced gastric cancer and by the FDA for two new indications second line non-small cell lung cancer and advanced gastric cancer in combination with paclitaxel.
Enabled by a fast track designation, we also completed the rolling FDA submission for necitumumab in first-line squamous non-small cell lung cancer. And we submitted necitumumab to European regulators for the same indication. On the clinical front along with Incyte, we announced that baricitinib met the primary end point of improved ACR20 response compared to placebo in the Phase 3 RA-BEACON study in patients with moderately-to-severely active rheumatoid arthritis who previously failed one or more TNF inhibitors. The study included a high percentage of patients who would also receive prior treatment with one or several non anti TNF biologic agents. Along with AstraZeneca, we announced the initiation of the Phase 2/3
AMARANTH study of AZD3293, an oral BACE inhibitor being studied for Alzheimer's disease. Earlier this month, we presented Phase 3 data ASCO-GI from the RAISE trial evaluating Cyramza in combination with chemotherapy in patients with metastatic colorectal cancer. In this trial, Ramucirumab prolonged both progression free and overall survival. And we began the second Phase 3 trial abemaciclib in breast cancer as well as a Phase 3 trial in lung cancer. On the business development front, we announced a pair of immuno-oncology collaborations. One with Bristol-Myers Squibb to study their PD-1 inhibitor,